These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7184420)

  • 1. [TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].
    Watanabe K; Satoh H; Ohki S; Furue H; Komita T; Iketa T; Ikenaga M; Arimori S; Nagao T; Yamamoto S
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):675-80. PubMed ID: 7184420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase I clinical study of a new fluorinated pyrimidine antineoplastic agent, TAC-278].
    Koyama Y
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):443-56. PubMed ID: 7184408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)].
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1821-6. PubMed ID: 7184376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
    Fujita F; Fujita M; Inaba H; Taguchi T
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):223-8. PubMed ID: 8434959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
    Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
    Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase II study of FF-705 by Clinical Cooperative Study Group].
    Gan To Kagaku Ryoho; 1984 Jan; 11(1):150-6. PubMed ID: 6230055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R; Tanabe K; Inoue H; Toge T
    Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tissue concentration of 5-FU following pre-operative administration of FT-207].
    Sarashina H; Ozaki A; Okamura T; Fukao K; Takase Y; Takeshima T; Todoroki T; Ishikawa A; Orii K; Nagoshi K; Iwasaki Y
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1277-84. PubMed ID: 6820912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biochemical modulation of 5-FU--effect of low dose CDDP].
    Hirata K; Yamamitsu S; Tsuji A; Shirasaka T; Mukaiya M; Oikawa I; Kimura H; Sasaki K; Denno R
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):467-75. PubMed ID: 10097743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Joint clinical Phase II study of SF-SP].
    Sato T; Sato H; Hanatani Y
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1210-7. PubMed ID: 6428321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of serum and tissue concentrations of FT-207 and 5-FU in patients with cancer of the large intestine following preoperative application of FT-207 suppositories].
    Okuda M; Teramoto T; Yoshida H; Sato K; Ushijima Y; Uematsu Y
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1580-8. PubMed ID: 6820920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
    Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the combination of BCNU, VCR and 5-FU in the treatment of disseminated neoplasms of the large intestine].
    Luporini G; Labianca R; Fraschini P; Tedeschi L
    Minerva Med; 1980 Mar; 71(10):773-9. PubMed ID: 7360363
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.